Irawati K. Kandela, Ph.D.
Affiliations: | 2006 | University of Wisconsin, Madison, Madison, WI |
Area:
Pharmacology, ImmunologyGoogle:
"Irawati Kandela"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Ralph M. Albrecht | grad student | 2006 | UW Madison | |
| (Development of metal nanoparticle immunoconjugates for correlative labeling in light and electron microscopy and as active targeted delivery systems.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Han H, Jain AD, Truica MI, et al. (2019) Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell |
| Frankowski KJ, Wang C, Patnaik S, et al. (2018) Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Science Translational Medicine. 10 |
| Kamoun W, Swindell E, Pien C, et al. (2018) Abstract 5771: Targeting EphA2 in bladder cancer using a novel antibody-directed nanotherapeutic Cancer Research. 78: 5771-5771 |
| Liu Y, Lou G, Norton JT, et al. (2017) 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology |
| Kandela IK, McAuliffe KJ, Cochran LE, et al. (2017) Discovery of the Antitumor Effects of a Porphyrazine Diol (Pz 285) in MDA-MB-231 Breast Tumor Xenograft Models in Mice. Acs Medicinal Chemistry Letters. 8: 705-709 |
| Aird F, Kandela I, Mantis C, et al. (2017) Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Elife. 6 |
| Kandela I, Aird F. (2017) Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression data. Elife. 6 |
| Mantis C, Kandela I, Aird F, et al. (2017) Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Elife. 6 |
| Hendrix MJ, Kandela I, Mazar AP, et al. (2016) Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. Laboratory Investigation; a Journal of Technical Methods and Pathology |
| Ravi D, Beheshti A, Abermil N, et al. (2016) Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC Dependent Cell Death in T-Cell and Hodgkin Lymphoma. Cancer Research |